Hematopoietic setm cell transplantation
Conditions
Interventions
Treatment group:PT/CY+ CSA/FK506+RUX
Control group:ATG+CSA/FK506+MMF+MTX
Sponsors
Henan Cancer Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 65 Years
Inclusion criteria
Inclusion criteria: ) Age: 40-65 years old; 2) Gender: both male and female; 3) Patients with hematologic malignancies (including acute leukemia-CR1, CR2, chronic myeloid leukemia-CP, and AP) in the standard risk group and myelodysplastic syndromes -RA,RARS,RCMD,RAEB-1, RAEB-2); 4) HLA-identical sibling allogeneic hematopoietic stem cell transplantation; 5) In general condition, ECOG score =1 6) Normal cardiac function: ejection fraction =50%; 7) Normal liver and renal function: blood bilirubin =35µmol/L, AST/ALT below 2 times the upper limit of normal value, blood muscle anhydride <= 130 mol/L; 8) Subjects sign informed consent.
Exclusion criteria
Exclusion criteria: (1) Severe infection was not controlled before transplantation; (2) severe allergy to ruxolitinib (anaphylactic shock or laryngeal edema); (3) Unrelated allogeneic hematopoietic stem cell transplantation, haploid transplantation and reduced pretreatment dose transplantation; (4) Patients with cardiac dysfunction (ejection fraction 130umol/L); (6) Liver dysfunction (total bilirubin >34umol/L,ALT, AST> 2 times the upper limit of normal); (7) Previous hematopoietic stem cell transplantation history; (8) Other circumstances that do not meet the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| acute graft-versus-host disease; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of infection;chornic graft-versus-host disease;non-relapse mortality;Overall survival;Disease-free survival; | — |
Countries
China
Contacts
Public Contactzhoujian
Henan cancer hospital
Outcome results
None listed